FUSED PROTEIN ELICITING IN VIVO ENHANCED ACTIVITY OF ERYTHROPOIETIN

FIELD: molecular biology, genetic and protein engineering. SUBSTANCE: invention relates to the fused protein eliciting in vivo the enhanced activity of erythropoietin. In the fused protein peptide fragment from carboxy-end of thrombopoietin amino acids 337-353 is fused with carboxy-end of human eryt...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KIM KI-VAN, OKH MIUNG-SUK, PARK DZI-SOOK, CHUNG BO-SUP, LI DONG-EOK
Format: Patent
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:FIELD: molecular biology, genetic and protein engineering. SUBSTANCE: invention relates to the fused protein eliciting in vivo the enhanced activity of erythropoietin. In the fused protein peptide fragment from carboxy-end of thrombopoietin amino acids 337-353 is fused with carboxy-end of human erythropoietin. Invention involves also nucleic acid encoding the fused protein and method for it preparing. The advantage of invention involves that the fused protein shows the significantly increased index half-life in vivo due to the enhanced level of carbohydrates being without loss of its activity that is typical for erythropoietin and it causes neither antigenicity in its application in human body. EFFECT: valuable medicinal properties of protein. 5 cl, 5 dwg, 6 ex